Can You Write Vyvanse with 3 Refills for Quarterly Follow-Up?
No, you cannot write a Vyvanse prescription with refills because it is a Schedule II controlled substance, which federal law prohibits from having refills. However, you can write multiple prescriptions dated for future fills (up to 90 days total supply) to align with your quarterly visit schedule, depending on your state regulations 1.
Federal Controlled Substance Regulations
Vyvanse (lisdexamfetamine) is classified as a Schedule II stimulant, and DEA regulations explicitly prohibit refills on Schedule II prescriptions. Each prescription requires a new written or electronic order from the prescriber.
Practical Solutions for Quarterly Monitoring
Option 1: Multiple Sequential Prescriptions (Preferred)
- Write three separate 30-day prescriptions at once, each dated for sequential monthly fills
- Mark "Do not fill until [date]" on prescriptions 2 and 3
- This provides a 90-day supply aligned with your quarterly visits
- State law varies: Some states (like New York, as mentioned in 1) explicitly allow prescriptions to be written for up to 3 months at once; verify your state's specific regulations
Option 2: Monthly Contact Protocol
- Write one 30-day prescription per month
- Maintain weekly telephone contact during initial titration 1
- Once stabilized, patients can receive new prescriptions monthly via:
- Secure electronic prescribing
- Phone authorization to pharmacy (where state law permits)
- Brief office visits for prescription pickup
Monitoring Requirements for Stable Patients
Children and adults with stable ADHD responses and no comorbidities can be seen every 3-4 months 1. The evidence supports this approach when:
- Target symptoms are well-controlled
- No significant side effects present
- No comorbid psychiatric conditions requiring closer monitoring
- Good medication adherence demonstrated
- No concerns about diversion or misuse
When More Frequent Visits Are Needed
Monthly visits are appropriate for 1:
- Initial titration phase (typically 2-4 weeks)
- Presence of side effects
- Complex comorbidities
- Adherence concerns
- Adolescents at risk for diversion 2
Key Monitoring Elements at Quarterly Visits
At each 3-month visit, systematically assess:
- Target ADHD symptoms using parent/teacher reports and rating scales 1
- Weight and vital signs at every visit (stimulants can cause appetite suppression and cardiovascular changes) 1
- Specific side effects: insomnia, anorexia, headaches, social withdrawal, tics 1
- Diversion risk in adolescents and young adults (Vyvanse has lower abuse potential than immediate-release amphetamines but remains a controlled substance) 2, 3, 4
- Self-ratings from adolescents and adults 1
Important Caveats
Diversion Concerns
While lisdexamfetamine has attenuated abuse liability compared to immediate-release dextroamphetamine due to its prodrug formulation 3, 4, it remains a Schedule II substance. Monitor prescription refill requests and symptom patterns for signs of misuse, particularly in adolescents and young adults 2.
State-Specific Regulations
Federal law sets the baseline (no refills), but state regulations vary significantly regarding:
- Whether multiple future-dated prescriptions are permitted
- Maximum days' supply per prescription
- Electronic prescribing requirements
- Verify your state medical board and pharmacy board regulations
Documentation
When writing multiple sequential prescriptions, document in the medical record:
- Clinical justification for 90-day supply
- Assessment of diversion risk
- Plan for monitoring between visits (e.g., phone check-ins, teacher reports)
The quarterly visit schedule is clinically appropriate for stable patients 1, but the prescription logistics require either multiple sequential prescriptions or more frequent brief contacts for new prescriptions due to Schedule II restrictions.